Male and female subjects will be eligible for participation in this study if they: Are ≥18 years on the day of screening Have a disease that is associated with a well characterized immunodeficiency (study population) Treated with an immunosuppressive therapy (study population) Have an immune-mediated disease without an immunosuppressive therapy, e.g. IBD patients solely with 5-ASA treatment (study population) Are clinically healthy and not vaccinated with a SARS-CoV-2 vaccine (control group, age and sex-matched) Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry

Male and female subjects will be eligible for participation in this study if they: Are ≥18 years on the day of screening Have a disease that is associated with a well characterized immunodeficiency (study population) Treated with an immunosuppressive therapy (study population) Have an immune-mediated disease without an immunosuppressive therapy, e.g. IBD patients solely with 5-ASA treatment (study population) Are clinically healthy and not vaccinated with a SARS-CoV-2 vaccine (control group, age and sex-matched) Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry